2009
DOI: 10.1111/j.1439-0531.2007.00986.x
|View full text |Cite
|
Sign up to set email alerts
|

Changes in Testicular Development, Ultrasonographic and Histological Appearance of the Testis in Buck Kids Immunized Against LHRH Using Recombinant LHRH Fusion Protein

Abstract: This study was designed to evaluate the effectiveness of recombinant Ovalbumin-LHRL (OL) immunization on changes in testicular size, histological appearance and testosterone production in buck kids. Thirty native buck kids at 18 weeks of age were divided into three groups, control (n = 10), immunization (n = 10) and castration (n = 10) groups. Immunized animals received OL protein generated by recombinant DNA technology. Ultrasonographic and histological examinations of the testes were performed. Animals were … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
1
0

Year Published

2010
2010
2022
2022

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(2 citation statements)
references
References 27 publications
1
1
0
Order By: Relevance
“…Similarly, Han et al (2015a) , after evaluating the effect of immunocastration in rams, obtained a reduction of 35.71% in the STD of the immunized group. This concurs with Ülker et al (2009) , who reported a reduction in testicular development, as well as in the STD due to immunocastration.…”
Section: Discussionsupporting
confidence: 91%
“…Similarly, Han et al (2015a) , after evaluating the effect of immunocastration in rams, obtained a reduction of 35.71% in the STD of the immunized group. This concurs with Ülker et al (2009) , who reported a reduction in testicular development, as well as in the STD due to immunocastration.…”
Section: Discussionsupporting
confidence: 91%
“…GonaCon™) or ovalbumin, with many of them available commercially for veterinary use. [11][12][13][14][15] Another recombinant fusion protein consisting of GnRH and diphtheria toxoid was successful in phase I/II clinical trials. 16 Synthetic subunit vaccine systems eliminate the need for large carrier proteins, which are often associated with adverse effects in the host.…”
Section: Introductionmentioning
confidence: 99%